PFG Investments LLC Boosts Position in Danaher Co. (NYSE:DHR)

PFG Investments LLC raised its position in Danaher Co. (NYSE:DHR) by 55.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 5,496 shares of the conglomerate’s stock after purchasing an additional 1,960 shares during the period. PFG Investments LLC’s holdings in Danaher were worth $1,528,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. nVerses Capital LLC purchased a new position in Danaher during the 2nd quarter valued at about $25,000. CarsonAllaria Wealth Management Ltd. purchased a new position in shares of Danaher during the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC acquired a new position in shares of Danaher during the 1st quarter worth approximately $30,000. MFA Wealth Advisors LLC purchased a new stake in Danaher in the 2nd quarter valued at approximately $51,000. Finally, Financial Connections Group Inc. acquired a new stake in Danaher during the 2nd quarter valued at $51,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the subject of a number of analyst reports. Stifel Nicolaus boosted their price target on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday. TD Cowen upped their target price on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday. Raymond James decreased their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research note on Wednesday. UBS Group cut their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Leerink Partners lifted their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, Danaher has an average rating of “Moderate Buy” and an average price target of $287.28.

Danaher Price Performance

DHR opened at $245.39 on Friday. The company has a 50 day moving average of $269.52 and a two-hundred day moving average of $260.42. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The company has a market cap of $181.76 billion, a P/E ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the firm earned $2.02 EPS. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. On average, analysts expect that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s payout ratio is currently 18.31%.

Insider Buying and Selling

In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Linda Filler sold 3,928 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the transaction, the director now owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,059 shares of company stock valued at $8,400,897. Corporate insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.